Test measures antibodies from HPV vaccine

Sept. 28, 2021

Scientists presented information at the 2021 AACC Annual Scientific Meeting & Clinical Expo on a new test to measure antibodies in girls who have received a vaccine for human papilloma virus (HPV), according to a news release.  

Meanwhile, other researchers at the meeting presented a study establishing accurate reference intervals for pregnant patients.

HPV is one of the most common sexually transmitted viruses, and research has clearly linked HPV infections to reproductive cancers in both women and men. In particular, most cases of cervical cancer are caused by HPV infection, the AACC said. 

Determining how long protection from HPV lasts after vaccination could help to bolster public confidence in the vaccine and increase uptake. With this in mind, a team led by Emmanuel Donkoh, PhD, of the University of Energy and Natural Resources in Sunyani, Ghana, created a rapid, high-throughput test to detect and quantify antibodies against HPV in Ghanaian girls. The scientists validated their test with blood samples from 49 pre-adolescent girls who received a quadrivalent HPV vaccine and 40 age-matched, unvaccinated girls. The test showed that immunoglobulin G antibodies for HPV-16 and -18 (common types of HPV) were much more prevalent among vaccinated girls three years after the third dose of the vaccine compared with unvaccinated girls (63.3% vs. 12.5% for HPV-16). 

Another obstacle in women’s health is the lack of standardized reference intervals for patients who are pregnant or have just given birth. To correctly interpret lab test results, providers must evaluate results within the context of reference intervals, which are the range of normal test values that indicate a person is healthy. However, pregnancy affects proteins and other biomarkers measured by common lab tests. This means that using existing reference intervals for pregnant patients can lead to incorrect interpretation of their lab results, which in turn can lead to subpar maternity care.  

Vilte Barakauskas, PhD, Ann Tran, MD, and colleagues from the BC Children’s and Women’s Hospital in Vancouver, Canada, have now established accurate reference intervals for coagulation tests commonly ordered for peripartum patients (i.e., patients who are about to or have just given birth). The research team collected and analyzed blood samples from an ethnically diverse group of more than 400 healthy patients with singleton pregnancies before and after delivery. Barakauskas’ team then calculated reference intervals using eligible test results from 196 of the participants. The new intervals revealed that peripartum patients have different levels of fibrinogen, von Willebrand factor, and other proteins involved in bleeding and clotting compared with non-pregnant adults. 

“Lab testing in pregnant women should be compared to reference intervals specific for pregnancy,” said Tran. “If a lab does not have pregnancy-specific reference intervals, then any out-of-range lab values should be interpreted cautiously and with knowledge of how pregnancy itself can change lab values.”  

Visit AACC for more news

ID 155685935 © Leigh Prather | Dreamstime.com
dreamstime_xxl_155685935
Photo 266192257 © Penchan Pumila | Dreamstime.com
Dreamstime Xxl 266192257
By Studio Romantic on Adobe Stock
Adobe Stock 414063009